Viking Therapeutics to Release Q1 2026 Financial Results and Host Conference Call
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy VKTX?
Source: PRnewswire
- Earnings Release Schedule: Viking Therapeutics plans to release its Q1 2026 financial results after market close on April 29, 2026, showcasing advancements in therapies for metabolic and endocrine disorders, which may impact investor confidence.
- Conference Call Details: The company will host a conference call at 4:30 p.m. ET on April 29, 2026, to discuss financial results and corporate updates, providing a direct communication channel between investors and management to enhance transparency.
- Clinical Trial Progress: Viking is conducting Phase 3 trials for VK2735 aimed at treating obesity, with preliminary data indicating good safety and tolerability, which, if successful, could significantly enhance the company's competitive position in the metabolic disease treatment market.
- New Drug Development Updates: VK2809 has shown significant efficacy in a Phase 2 trial for non-alcoholic fatty liver disease, and if further validated, it could open new revenue streams for the company and strengthen its market position.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VKTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VKTX
Wall Street analysts forecast VKTX stock price to rise
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 33.800
Low
70.00
Averages
97.00
High
125.00
Current: 33.800
Low
70.00
Averages
97.00
High
125.00
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Viking Therapeutics to Release Q1 2026 Financial Results
- Earnings Release Schedule: Viking Therapeutics plans to announce its Q1 2026 financial results after market close on April 29, 2026, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: The company will host a conference call at 4:30 PM ET on the same day, with participants able to dial in at 844-850-0543 (U.S.) or 412-317-5199 (international) to gain insights into financial results and corporate updates.
- Live Webcast Availability: The conference call will be available via live webcast on Viking's website, enhancing investor engagement, and a replay will be accessible for 30 days post-call, ensuring widespread dissemination of information.
- R&D Progress Overview: Viking Therapeutics focuses on innovative therapies for metabolic and endocrine disorders, with ongoing clinical trials for VK2735 and VK2809, showcasing the company's sustained innovation capacity and market potential in the biopharmaceutical sector.
See More
Viking Therapeutics to Release Q1 2026 Financial Results and Host Conference Call
- Earnings Release Schedule: Viking Therapeutics plans to release its Q1 2026 financial results after market close on April 29, 2026, showcasing advancements in therapies for metabolic and endocrine disorders, which may impact investor confidence.
- Conference Call Details: The company will host a conference call at 4:30 p.m. ET on April 29, 2026, to discuss financial results and corporate updates, providing a direct communication channel between investors and management to enhance transparency.
- Clinical Trial Progress: Viking is conducting Phase 3 trials for VK2735 aimed at treating obesity, with preliminary data indicating good safety and tolerability, which, if successful, could significantly enhance the company's competitive position in the metabolic disease treatment market.
- New Drug Development Updates: VK2809 has shown significant efficacy in a Phase 2 trial for non-alcoholic fatty liver disease, and if further validated, it could open new revenue streams for the company and strengthen its market position.
See More
Trump Extends Ceasefire with Iran Amid Market Volatility
- Ceasefire Extension: President Trump announced the extension of the ceasefire with Iran, originally set to expire today, until Tehran presents a 'unified proposal,' aiming to ease tensions in the Middle East, which could impact global oil prices.
- Boeing Earnings Beat: Boeing reported a smaller-than-expected loss per share in Q1 and exceeded revenue expectations, leading to a more than 3% rise in its stock price, indicating a gradual recovery in a challenging aviation market that may boost investor confidence.
- Fed Nominee Scrutiny: Kevin Warsh, Trump's nominee for Federal Reserve Chair, faced tough questions during his confirmation hearing regarding his independence and financial background, despite asserting he wouldn't lower interest rates solely at Trump's request, potentially affecting market expectations for Fed policy.
- Best Buy's New CEO: Best Buy announced that insider Jason Bonfig will succeed CEO Corie Barry on October 31, tasked with driving sales amid a lukewarm market while the company seeks to enhance its presence in the artificial intelligence product sector.
See More
Trump Extends Ceasefire with Iran Amid Market Volatility
- Ceasefire Extension: Trump announced the extension of the ceasefire with Iran, originally set to expire today, now lasting until Tehran provides a 'unified proposal', aiming to alleviate market concerns over geopolitical risks, which could positively impact oil prices and stock markets.
- Boeing Stock Surge: Boeing shares rose over 3% this morning after the company reported a smaller-than-expected loss per share and exceeded revenue expectations in Q1, demonstrating resilience during tough times, with the CEO set to discuss results on CNBC today, further boosting market confidence.
- Fed Nominee Scrutiny: Kevin Warsh, Trump's nominee for the Federal Reserve chair, faced tough questions during his confirmation hearing, asserting he wouldn't lower interest rates at Trump's request, raising concerns about his independence and financial background, which may influence market expectations for future monetary policy.
- Amazon Enters GLP-1 Market: Amazon's primary care arm launched a new program to ease access to weight-loss drugs, enhancing its competitiveness in the healthcare sector while potentially boosting the market performance of related stocks, reflecting the company's strategic expansion into pharmaceuticals.
See More
Viking Therapeutics Q1 Earnings Preview Highlights Losses and Market Potential
- Earnings Loss Forecast: Koyfin estimates a Q1 GAAP loss per share of $1.03 for Viking Therapeutics, widening from a $0.4 loss a year earlier, indicating ongoing losses during the clinical development phase with zero expected revenue as commercial sales have not yet commenced.
- Clinical Trial Progress: Investor focus remains on the Vanquish program, which completed enrollment for Vanquish-2 in March, evaluating a 78-week weight reduction treatment, reflecting strong demand for additional obesity treatment options as noted by CEO Brian Lian regarding rapid enrollment.
- Intensifying Market Competition: The obesity drug market is becoming increasingly competitive, with Viking's main rival Structure Therapeutics reporting over 16% weight loss from its oral GLP-1 candidate over ten months, while Amazon has launched an integrated GLP-1 treatment platform, intensifying competition in the sector.
- Analyst Optimism: Despite the anticipated losses, Koyfin projects a 174% upside for VKTX stock with a 12-month price target of $92.72, as coverage from 19 analysts mostly reflects a 'Strong Buy' consensus, indicating market confidence in its obesity drug development.
See More
Amazon Launches GLP-1 Management Program to Transform Weight Loss Treatment
- Market Expansion: Amazon is launching a new GLP-1 management program through its primary care arm, Amazon One Medical, aiming to integrate obesity treatment into routine care, which is expected to significantly enhance patient adherence to long-term weight management.
- Transparent Pricing: The program offers insured pricing starting as low as $25 per month, while cash-paying patients will find oral medications starting at $149 per month and injectable treatments like Wegovy at $299, positioning Amazon competitively in the market despite similar pricing.
- Convenient Services: Amazon Pharmacy will provide on-demand prescription renewals, starting at $29 for message consultations and $49 for video care, which is likely to attract more customers and enhance loyalty and market share.
- Logistical Advantage: Amazon plans to expand its same-day drug delivery service to 4,500 cities by the end of 2026, leveraging its robust logistics network and consumer reach to solidify its position within the healthcare system.
See More
Viking Therapeutics to Release Q1 2026 Financial Results
- Earnings Release Schedule: Viking Therapeutics plans to announce its Q1 2026 financial results after market close on April 29, 2026, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: The company will host a conference call at 4:30 PM ET on the same day, with participants able to dial in at 844-850-0543 (U.S.) or 412-317-5199 (international) to gain insights into financial results and corporate updates.
- Live Webcast Availability: The conference call will be available via live webcast on Viking's website, enhancing investor engagement, and a replay will be accessible for 30 days post-call, ensuring widespread dissemination of information.
- R&D Progress Overview: Viking Therapeutics focuses on innovative therapies for metabolic and endocrine disorders, with ongoing clinical trials for VK2735 and VK2809, showcasing the company's sustained innovation capacity and market potential in the biopharmaceutical sector.
See More
Viking Therapeutics to Release Q1 2026 Financial Results and Host Conference Call
- Earnings Release Schedule: Viking Therapeutics plans to release its Q1 2026 financial results after market close on April 29, 2026, showcasing advancements in therapies for metabolic and endocrine disorders, which may impact investor confidence.
- Conference Call Details: The company will host a conference call at 4:30 p.m. ET on April 29, 2026, to discuss financial results and corporate updates, providing a direct communication channel between investors and management to enhance transparency.
- Clinical Trial Progress: Viking is conducting Phase 3 trials for VK2735 aimed at treating obesity, with preliminary data indicating good safety and tolerability, which, if successful, could significantly enhance the company's competitive position in the metabolic disease treatment market.
- New Drug Development Updates: VK2809 has shown significant efficacy in a Phase 2 trial for non-alcoholic fatty liver disease, and if further validated, it could open new revenue streams for the company and strengthen its market position.
See More
Trump Extends Ceasefire with Iran Amid Market Volatility
- Ceasefire Extension: President Trump announced the extension of the ceasefire with Iran, originally set to expire today, until Tehran presents a 'unified proposal,' aiming to ease tensions in the Middle East, which could impact global oil prices.
- Boeing Earnings Beat: Boeing reported a smaller-than-expected loss per share in Q1 and exceeded revenue expectations, leading to a more than 3% rise in its stock price, indicating a gradual recovery in a challenging aviation market that may boost investor confidence.
- Fed Nominee Scrutiny: Kevin Warsh, Trump's nominee for Federal Reserve Chair, faced tough questions during his confirmation hearing regarding his independence and financial background, despite asserting he wouldn't lower interest rates solely at Trump's request, potentially affecting market expectations for Fed policy.
- Best Buy's New CEO: Best Buy announced that insider Jason Bonfig will succeed CEO Corie Barry on October 31, tasked with driving sales amid a lukewarm market while the company seeks to enhance its presence in the artificial intelligence product sector.
See More
Trump Extends Ceasefire with Iran Amid Market Volatility
- Ceasefire Extension: Trump announced the extension of the ceasefire with Iran, originally set to expire today, now lasting until Tehran provides a 'unified proposal', aiming to alleviate market concerns over geopolitical risks, which could positively impact oil prices and stock markets.
- Boeing Stock Surge: Boeing shares rose over 3% this morning after the company reported a smaller-than-expected loss per share and exceeded revenue expectations in Q1, demonstrating resilience during tough times, with the CEO set to discuss results on CNBC today, further boosting market confidence.
- Fed Nominee Scrutiny: Kevin Warsh, Trump's nominee for the Federal Reserve chair, faced tough questions during his confirmation hearing, asserting he wouldn't lower interest rates at Trump's request, raising concerns about his independence and financial background, which may influence market expectations for future monetary policy.
- Amazon Enters GLP-1 Market: Amazon's primary care arm launched a new program to ease access to weight-loss drugs, enhancing its competitiveness in the healthcare sector while potentially boosting the market performance of related stocks, reflecting the company's strategic expansion into pharmaceuticals.
See More
Viking Therapeutics Q1 Earnings Preview Highlights Losses and Market Potential
- Earnings Loss Forecast: Koyfin estimates a Q1 GAAP loss per share of $1.03 for Viking Therapeutics, widening from a $0.4 loss a year earlier, indicating ongoing losses during the clinical development phase with zero expected revenue as commercial sales have not yet commenced.
- Clinical Trial Progress: Investor focus remains on the Vanquish program, which completed enrollment for Vanquish-2 in March, evaluating a 78-week weight reduction treatment, reflecting strong demand for additional obesity treatment options as noted by CEO Brian Lian regarding rapid enrollment.
- Intensifying Market Competition: The obesity drug market is becoming increasingly competitive, with Viking's main rival Structure Therapeutics reporting over 16% weight loss from its oral GLP-1 candidate over ten months, while Amazon has launched an integrated GLP-1 treatment platform, intensifying competition in the sector.
- Analyst Optimism: Despite the anticipated losses, Koyfin projects a 174% upside for VKTX stock with a 12-month price target of $92.72, as coverage from 19 analysts mostly reflects a 'Strong Buy' consensus, indicating market confidence in its obesity drug development.
See More
Amazon Launches GLP-1 Management Program to Transform Weight Loss Treatment
- Market Expansion: Amazon is launching a new GLP-1 management program through its primary care arm, Amazon One Medical, aiming to integrate obesity treatment into routine care, which is expected to significantly enhance patient adherence to long-term weight management.
- Transparent Pricing: The program offers insured pricing starting as low as $25 per month, while cash-paying patients will find oral medications starting at $149 per month and injectable treatments like Wegovy at $299, positioning Amazon competitively in the market despite similar pricing.
- Convenient Services: Amazon Pharmacy will provide on-demand prescription renewals, starting at $29 for message consultations and $49 for video care, which is likely to attract more customers and enhance loyalty and market share.
- Logistical Advantage: Amazon plans to expand its same-day drug delivery service to 4,500 cities by the end of 2026, leveraging its robust logistics network and consumer reach to solidify its position within the healthcare system.
See More
